purpose effects age comorbidity treatment outcomes patients limited stage lung cancer unclear study analyzes relapse survival population according age comorbidity methods retrospective review performed NUMBER patients referred british columbia cancer agency vancouver island centre january NUMBER december NUMBER patient treatment characteristics disease response relapse survival compared age cohorts NUMBER years n NUMBER NUMBER years n NUMBER NUMBER NUMBER years n NUMBER NUMBER according charlson comorbidity scores NUMBER NUMBER NUMBER multivariate analysis performed identify independent prognostic factors associated treatment response survival results patient factors significantly differed age functional status classified eastern cooperative oncology group performance status number comorbidities increasing age significantly associated fewer diagnostic scans combined modality chemoradiotherapy crt given NUMBER NUMBER NUMBER patients ages NUMBER NUMBER years respectively p NUMBER thoracic irradiation use comparable age cohorts p NUMBER chemotherapy use varied significantly intensive regimens fewer cycles lower total doses advancing age p NUMBER prophylactic cranial irradiation pci used NUMBER patients NUMBER age NUMBER years overall response rates primary treatment significantly decreased advancing age NUMBER NUMBER NUMBER patients ages NUMBER NUMBER years respectively p NUMBER treatment toxicity relapse patterns similar age cohorts overall survival rates significantly lower advancing age NUMBER NUMBER NUMBER p NUMBER corresponding median survivals NUMBER NUMBER NUMBER months patients ages NUMBER NUMBER years respectively multivariate analysis age charlson comorbidity scores significantly associated treatment response survival independent prognostic factors favorably associated survival good performance status normal lactate dehydrogenase absence pleural effusion cycles chemotherapy conclusion increasing age associated decreased performance status increased comorbidity older patients likely treated crt intensive chemotherapy pci treatment response survival rates lower advancing age attributed poor performance status suboptimal treatment age references NUMBER small cell l sclc community based l sclc l sclc NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER year NUMBER NUMBER l sclc